PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Green light for one of Europe’s largest life sciences campus

UBS Asset Management and Reef Group secure approval for the Stevenage-based facility.

Reef Group and UBS Asset Management have gained approval to develop one of Europe’s largest life sciences campuses in Stevenage, UK.

The positive decision came from Stevenage Borough Council’s planning committee and will pave the way for a new life sciences hub. The development will be delivered alongside GSK’s existing global R&D facility and the wider ecosystem at Stevenage Bioscience Catalyst.

It is expected to provide a sustainable and connected life science campus that combines companies from early-stage through to commercialisation, while also helping organisations reach the increasing demand for manufacturing and laboratory space in the UK.

The 15-building campus, called ‘Elevate Quarter’, will comprise a variety of different uses, including research and development offices, manufacturing facilities and flexible lab buildings, as well as training, innovation and collaboration spaces.

The new facility will boost Stevenage’s established reputation as Europe’s leading cluster for advanced therapies. Indeed, it is home to more than 40 organisations employing over 3,500 people.

Piers Slater, joint chief executive at Reef Group, was delighted about the decision: “The approval of our new life sciences campus in Stevenage further cements its position as Europe’s leading cluster for advanced therapies. Stevenage is ideally positioned to attract world-class talent and the campus will facilitate further collaboration between major multinationals and biotechs.”

Olivia Drew, portfolio manager, real estate and private markets at UBS Asset Management, reflected: “The delivery of the new life sciences campus will leverage years of unparalleled experience across both UBS and Reef. The buildings have been carefully designed to be at the cutting edge of sustainability and will facilitate world-leading R&D and advanced manufacturing. The new campus will support thousands of new jobs and boost the UK’s position as a global life sciences leader.”

Dr Tony Wood, chief scientific officer at GSK, concluded: “New lab space and facilities for the cutting-edge biotech companies of the future are in short supply, so we’re delighted to support the creation of a new life sciences campus at the heart of the Golden Triangle of London, Oxford and Cambridge.

“Situated alongside one of our global R&D hubs, this is a really positive development for the sector and it’s great that we’re one step closer to work starting on the new Stevenage development.”

Construction is expected to start in late 2023 with completion for phase one targeted for the fourth quarter of 2025.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026